Last reviewed · How we verify
TQB3454 Tablets
TQB3454 is designed to inhibit the activity of a specific enzyme involved in the progression of certain cancers.
TQB3454 is designed to inhibit the activity of a specific enzyme involved in the progression of certain cancers. Used for Advanced solid tumors.
At a glance
| Generic name | TQB3454 Tablets |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By targeting this enzyme, TQB3454 aims to disrupt the metabolic pathways that support tumor growth and survival, potentially leading to reduced tumor size and slowed disease progression.
Approved indications
- Advanced solid tumors
Common side effects
- Nausea
- Fatigue
Key clinical trials
- A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma. (PHASE3)
- A Study of TQB3454 Tablets in Patients With Blood Tumors (PHASE1, PHASE2)
- A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects (PHASE1)
- A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQB3454 Tablets CI brief — competitive landscape report
- TQB3454 Tablets updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI